{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:38Z","timestamp":1747207358979,"version":"3.40.5"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2021,4]]},"abstract":"\nBackground:<\/jats:title>\nIn our previous studies, we had demonstrated the efficiency and specificity\nof constructed bladder tissue-specific adenovirus Ad-PSCAE-UPII-E1A-AR (APU-EIA-AR) on\nbladder cancer. The virus biodistribution and body toxicity in nude mice have also been investigated.\nHowever, the safety of the bladder cancer-specific oncolytic adenovirus on fetal mice and F1\nmice should be under intense investigation.<\/jats:p>\n<\/jats:sec>\n\nObjectives:<\/jats:title>\nIn order to evaluate the teratogenic toxicity of bladder cancer-specific oncolytic adenovirus\nAPU-EIA-AR on mice, in this study, we investigated the fetal mice weight, fetal body\nlength and tail length, fetal skeleton development, as well as the F1 mice weight, growth curve, and\nmajor organ pathology. These teratogenic toxicity data of bladder tissue-specific adenovirus Ad-PSCAE-\nUPII-E1A-AR (AD) would provide safe information prior to embarking on clinical trials.<\/jats:p>\n<\/jats:sec>\n\nMethods:<\/jats:title>\n On the sixth day of being fertilized, the pregnant mice began to be intramuscularly administrated\nwith AD (1\u00d7107<\/jats:sup>VP, 1\u00d7108<\/jats:sup>VP, 1\u00d7109<\/jats:sup>VP) every other day for ten days. The pregnant\nmice were then divided into two groups. One group was euthanized on the seventeenth day; the fetal\nmice were taken out, and the bone structure of the infants was observed. The other group was\nobserved until natural childbirth. The Filial Generation (F1) is fed for 30 days; the variations in the\ngrowth progress and development were assessed. The mice were then euthanized; The tissues from\nmajor organs were harvested and observed under the microscope.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nIn the process of teratogenic toxicity test, the Placenta weight, fetal mice weight, body\nlength, and a tail length of mice fetal in adenovirus treated group did not reveal any alteration.\nMeanwhile, comparing with the PBS group, there is no obvious change in the skeleton of fetal\nmice treated with adenovirus. During the development process of F1 mice treated with adenovirus,\nthe changes in mice weight show statistical significance. However, in the progress of the growth\ncurve, this difference is not very obvious. Furthermore, the pathological section showed no obvious\nalteration in major organs.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nOur study demonstrated that bladder cancer-specific adenovirus Ad-PSCAE-UPII-\nE1A-AR appears safe in pregnant mice without any discernable effects on fetal mice and F1 development.\nHence, it is relatively safe for tumor gene therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220999201217161258","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T07:26:13Z","timestamp":1608276373000},"page":"160-166","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice"],"prefix":"10.2174","volume":"21","author":[{"given":"Keqing","family":"Lu","sequence":"first","affiliation":[{"name":"Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-3788","authenticated-orcid":true,"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Medical Experiments, School of Basic Medical Sciences, Lanzhou University, Gansu Province, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoliang","family":"Ma","sequence":"additional","affiliation":[{"name":"Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Cao","sequence":"additional","affiliation":[{"name":"Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[{"name":"Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900,United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900,United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Gansu Nephro-Urological Clinical Center, Key Laboratory of Urological Diseases, Gansu Province (Lanzhou University), Institute of Urology, The Second Hospital of Lanzhou University, Lanzhou730000,China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11934-018-0860-6","volume":"19","author":"Bhanvadia S.K.","year":"2018","unstructured":"Bhanvadia S.K.; Bladder Cancer Survivorship. Curr Urol Rep 2018,19(12),111","journal-title":"Curr Urol Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","volume":"374","author":"Kaufman D.S.","year":"2009","unstructured":"Kaufman D.S.; Shipley W.U.; Feldman A.S.; Bladder cancer. Lancet 2009,374(9685),239-249","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ncpuro1202","volume":"5","author":"Ghoneim M.A.","year":"2008","unstructured":"Ghoneim M.A.; Abol-Enein H.; Management of muscle-invasive bladder cancer: an update. Nat Clin Pract Urol 2008,5(9),501-508","journal-title":"Nat Clin Pract Urol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(03)01168-9","volume":"4","author":"Hussain S.A.","year":"2003","unstructured":"Hussain S.A.; James N.D.; The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003,4(8),489-497","journal-title":"Lancet Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","volume":"21","author":"Rosewell Shaw A.","year":"2016","unstructured":"Rosewell Shaw A.; Suzuki M.; Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol 2016,21,9-15","journal-title":"Curr Opin Virol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","volume":"17","author":"Man Y.K.S.","year":"2018","unstructured":"Man Y.K.S.; Davies J.A.; Coughlan L.; Pantelidou C.; Blázquez-Moreno A.; Marshall J.F.; Parker A.L.; Halldén G.; The Novel Oncolytic Adenoviral Mutant Ad5-3\u0394-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells. Mol Cancer Ther 2018,17(2),575-587","journal-title":"Mol Cancer Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"eaat9321","DOI":"10.1126\/scitranslmed.aat9321","volume":"11","author":"Pascual-Pasto G.","year":"2019","unstructured":"Pascual-Pasto G.; Bazan-Peregrino M.; Olaciregui N.G.; Restrepo-Perdomo C.A.; Mato-Berciano A.; Ottaviani D.; Weber K.; Correa G.; Paco S.; Vila-Ubach M.; Cuadrado-Vilanova M.; Castillo-Ecija H.; Botteri G.; Garcia-Gerique L.; Moreno-Gilabert H.; Gimenez-Alejandre M.; Alonso-Lopez P.; Farrera-Sal M.; Torres-Manjon S.; Ramos-Lozano D.; Moreno R.; Aerts I.; Doz F.; Cassoux N.; Chapeaublanc E.; Torrebadell M.; Roldan M.; König A.; Suñol M.; Claverol J.; Lavarino C.; Carmen de T.; Fu L.; Radvanyi F.; Munier F.L.; Catalá-Mora J.; Mora J.; Alemany R.; Cascalló M.; Chantada G.L.; Carcaboso A.M.; Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Sci Transl Med 2019,11(476),eaat9321","journal-title":"Sci Transl Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000200802","volume":"82","author":"He X.D.","year":"2009","unstructured":"He X.D.; Wang Z.P.; Wei H.Y.; Zhou Q.; Wang D.G.; Tian J.Q.; Fu S.J.; Rodriguez R.; Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell. Urol Int 2009,82(2),209-213","journal-title":"Urol Int"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/sj.mt.6300223","volume":"15","author":"Hoti N","year":"2007","unstructured":"Hoti N; Li Y; Chen CL; Chowdhury WH; Johns DC; Xia Q; Kabul A; Hsieh JT; Berg M; Ketner G; Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Molecular therapy : the journal of the American Society of Gene Therapy 2007,15(8),1495-1503","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/gt.2011.180","volume":"19","author":"Zhai Z.","year":"2012","unstructured":"Zhai Z.; Wang Z.; Fu S.; Lu J.; Wang F.; Li R.; Zhang H.; Li S.; Hou Z.; Wang H.; Rodriguez R.; Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther 2012,19(11),1065-1074","journal-title":"Gene Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1007\/s13277-014-2353-7","volume":"35","author":"Wang L.","year":"2014","unstructured":"Wang L.; Zhang Y.; Zhao J.; Xiao E.; Lu J.; Fu S.; Wang Z.; Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro. Tumour Biol 2014,35(11),10879-10890","journal-title":"Tumour Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.3892\/ol.2017.6416","volume":"14","author":"Li S.","year":"2017","unstructured":"Li S.; Wang F.; Zhai Z.; Fu S.; Lu J.; Zhang H.; Guo H.; Hu X.; Li R.; Wang Z.; Rodriguez R.; Synergistic effect of bladder cancer-specific oncolytic adenovirus in combination with chemotherapy. Oncol Lett 2017,14(2),2081-2088","journal-title":"Oncol Lett"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/09553002.2017.1231942","volume":"93","author":"Zhang H.","year":"2017","unstructured":"Zhang H.; Wang F.; Mao C.; Zhang Z.; Fu S.; Lu J.; Zhai Z.; Li R.; Li S.; Rodriguez R.; Wang Z.; Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells. Int J Radiat Biol 2017,93(2),174-183","journal-title":"Int J Radiat Biol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4161\/cbt.8.8.7913","volume":"8","author":"Chang J.","year":"2009","unstructured":"Chang J.; Zhao X.; Wu X.; Guo Y.; Guo H.; Cao J.; Guo Y.; Lou D.; Yu D.; Li J.; A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009,8(8),676-682","journal-title":"Cancer Biol Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-10-0791","volume":"16","author":"Kimball KJ","year":"2010","unstructured":"Kimball KJ; Preuss MA; Barnes MN; Wang M; Siegal GP; Wan W; Kuo H; Saddekni S; Stockard CR; Grizzle WE; A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 2010,16(21),5277-5287","journal-title":"Clin Cancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1089\/hum.2009.206","volume":"21","author":"Schenk E.","year":"2010","unstructured":"Schenk E.; Essand M.; Bangma C.H.; Barber C.; Behr J.P.; Briggs S.; Carlisle R.; Cheng W.S.; Danielsson A.; Dautzenberg I.J.; Dzojic H.; Erbacher P.; Fisher K.; Frazier A.; Georgopoulos L.J.; Hoeben R.; Kochanek S.; Koppers-Lalic D.; Kraaij R.; Kreppel F.; Lindholm L.; Magnusson M.; Maitland N.; Neuberg P.; Nilsson B.; Ogris M.; Remy J.S.; Scaife M.; Schooten E.; Seymour L.; Totterman T.; Uil T.G.; Ulbrich K.; Veldhoven-Zweistra J.L.; de Vrij J.; van Weerden W.; Wagner E.; Willemsen R.; Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther GIANT FP6 Consortium2010,21(7),807-813","journal-title":"Hum Gene Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0182715","DOI":"10.1371\/journal.pone.0182715","volume":"12","author":"Kuryk L.","year":"2017","unstructured":"Kuryk L.; Vassilev L.; Ranki T.; Hemminki A.; Karioja-Kallio A.; Levälampi O.; Vuolanto A.; Cerullo V.; Pesonen S.; Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment. PLoS One 2017,12(8),e0182715","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13311-017-0516-0","volume":"14","author":"Foreman P.M.","year":"2017","unstructured":"Foreman P.M.; Friedman G.K.; Cassady K.A.; Markert J.M.; Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics 2017,14(2),333-344","journal-title":"Neurotherapeutics"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJM199203053261003","volume":"326","author":"Fowler K.B.","year":"1992","unstructured":"Fowler K.B.; Stagno S.; Pass R.F.; Britt W.J.; Boll T.J.; Alford C.A.; The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992,326(10),663-667","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2006.01.004","volume":"36","author":"de Jong EP","year":"2006","unstructured":"de Jong EP; de Haan TR; Kroes AC; Beersma MF; Oepkes D; Walther FJ; Parvovirus B19 infection in pregnancy. J Clin Virol 2006,36(1),1-7","journal-title":"J Clin Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156652312800099599","volume":"12","author":"Wang F.","year":"2012","unstructured":"Wang F.; Wang Z.; Tian H.; Qi M.; Zhai Z.; Li S.; Li R.; Zhang H.; Wang W.; Fu S.; Lu J.; Rodriguez R.; Guo Y.; Zhou L.; Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr Gene Ther 2012,12(2),67-76","journal-title":"Curr Gene Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","volume":"7","author":"Machiels J.P.","year":"2019","unstructured":"Machiels J.P.; Salazar R.; Rottey S.; Duran I.; Dirix L.; Geboes K.; Wilkinson-Blanc C.; Pover G.; Alvis S.; Champion B.; Fisher K.; McElwaine-Johnn H.; Beadle J.; Calvo E.; A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer 2019,7(1),20","journal-title":"J Immunother Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/13543784.2019.1694000","volume":"28","author":"Philbrick B.","year":"2019","unstructured":"Philbrick B.; Adamson D.C.; DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Expert Opin Investig Drugs 2019,28(12),1041-1049","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"E33","DOI":"10.3390\/biomedicines6010033","volume":"6","author":"Yokoda R.T.","year":"2018","unstructured":"Yokoda R.T.; Nagalo B.M.; Borad M.J.; Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines 2018,6(1),E33","journal-title":"Biomedicines"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.urology.2007.07.003","volume":"70","author":"Terao S.","year":"2007","unstructured":"Terao S.; Shirakawa T.; Kubo S.; Bishunu A.; Lee S.J.; Goda K.; Tsukuda M.; Hamada K.; Tagawa M.; Takenaka A.; Fujisawa M.; Gotoh A.; Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology 2007,70(5),1009-1013","journal-title":"Urology"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","volume":"12","author":"Ramesh N","year":"2006","unstructured":"Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC; CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006,12(1),305-313","journal-title":"Clin Cancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ymthe.2004.07.002","volume":"10","author":"Ramesh N","year":"2004","unstructured":"Ramesh N; Memarzadeh B; Ge Y; Frey D; VanRoey M; Rojas V; Yu DC; Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther 2004,10(4),697-705","journal-title":"Mol Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.urology.2006.04.021","volume":"68","author":"Wang H.","year":"2006","unstructured":"Wang H.; Satoh M.; Abe H.; Sunamura M.; Moriya T.; Ishidoya S.; Saito S.; Hamada H.; Arai Y.; Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Urology 2006,68(3),674-681","journal-title":"Urology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"Ahi Y.S.","year":"2011","unstructured":"Ahi Y.S.; Bangari D.S.; Mittal S.K.; Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011,11(4),307-320","journal-title":"Curr Gene Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2174\/156652307780859062","volume":"7","author":"Campos S.K.","year":"2007","unstructured":"Campos S.K.; Barry M.A.; Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007,7(3),189-204","journal-title":"Curr Gene Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e476s","DOI":"10.6061\/clinics\/2018\/e476s","volume":"73","author":"Tamura R.E.","year":"2018","unstructured":"Tamura R.E.; de Luna I.V.; Lana M.G.; Strauss B.E.; Improving adenoviral vectors and strategies for prostate cancer gene therapy. Clinics 2018,73(Suppl. 1),e476s","journal-title":"Clinics"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1002\/jcp.27850","volume":"234","author":"Goradel N.H.","year":"2019","unstructured":"Goradel N.H.; Mohajel N.; Malekshahi Z.V.; Jahangiri S.; Najafi M.; Farhood B.; Mortezaee K.; Negahdari B.; Arashkia A.; Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. J Cell Physiol 2019,234(6),8636-8646","journal-title":"J Cell Physiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/clinids\/13.2.315","volume":"13","author":"Demmler G.J.","year":"1991","unstructured":"Demmler G.J.; Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991,13(2),315-329","journal-title":"Rev Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/rmv.395","volume":"13","author":"Chisaka H.","year":"2003","unstructured":"Chisaka H.; Morita E.; Yaegashi N.; Sugamura K.; Parvovirus B19 and the pathogenesis of anaemia. Rev Med Virol 2003,13(6),347-359","journal-title":"Rev Med Virol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1086\/342575","volume":"35","author":"Norbeck O.","year":"2002","unstructured":"Norbeck O.; Papadogiannakis N.; Petersson K.; Hirbod T.; Broliden K.; Tolfvenstam T.; Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin Infect Dis 2002,35(9),1032-1038","journal-title":"Clin Infect Dis"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/189228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/189228\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/189228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T14:50:09Z","timestamp":1645973409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/189228\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220999201217161258","relation":{},"ISSN":["1566-5232"],"issn-type":[{"type":"print","value":"1566-5232"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}